Edition:
India

Clearside Biomedical Inc (CLSD.OQ)

CLSD.OQ on NASDAQ Stock Exchange Global Market

0.73USD
20 Sep 2019
Change (% chg)

$-0.01 (-1.06%)
Prev Close
$0.74
Open
$0.74
Day's High
$0.75
Day's Low
$0.71
Volume
45,157
Avg. Vol
160,394
52-wk High
$6.61
52-wk Low
$0.56

Latest Key Developments (Source: Significant Developments)

Regenxbio Announces Exclusive Worldwide Option And License Agreement With Clearside Biomedical
Wednesday, 4 Sep 2019 

Sept 4 (Reuters) - Regenxbio Inc ::REGENXBIO ANNOUNCES EXCLUSIVE WORLDWIDE OPTION AND LICENSE AGREEMENT WITH CLEARSIDE BIOMEDICAL FOR EVALUATION OF IN-OFFICE DELIVERY PLATFORM FOR RGX-314.REGENXBIO INC - PLANS TO EVALUATE RGX-314 USING CLEARSIDE'S SCS MICROINJECTOR FOR IN-OFFICE, NON-SURGICAL DELIVERY INTO SUPRACHOROIDAL SPACE.REGENXBIO - IN RETURN FOR RIGHTS,CLEARSIDE TO RECEIVE FEE UPON CO'S EXERCISE OF OPTION, $34 MILLION IN DEVELOPMENT MILESTONES ACROSS MULTIPLE INDICATIONS.REGENXBIO INC - CLEARSIDE TO RECEIVE UP TO $102 MILLION IN SALES MILESTONES & MID-SINGLE DIGIT ROYALTIES ON NET SALES OF PRODUCTS USING SCS MICROINJECTOR.REGENXBIO INC - CO WILL BE RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES FOR GENE THERAPY PRODUCT CANDIDATES.REGENXBIO - UNDER AGREEMENT, CLEARSIDE TO BE RESPONSIBLE FOR SUPPLYING SCS MICROINJECTOR, SUPPORTING PRECLINICAL STUDIES,CLINICAL STUDIES,COMMERCIAL USE.  Full Article

Clearside Biomedical Provides New Drug Application Update For Xipere
Thursday, 22 Aug 2019 

Aug 22 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL PROVIDES NEW DRUG APPLICATION UPDATE FOR XIPEREᵀᴹ (TRIAMCINOLONE ACETONIDE SUPRACHOROIDAL INJECTABLE SUSPENSION).CLEARSIDE BIOMEDICAL INC - PLANS TO RE-SUBMIT NDA IN Q1 OF 2020 WITH REQUESTED STABILITY DATA..CLEARSIDE BIOMEDICAL INC - CLEARSIDE EXPECTS TO RECEIVE A COMPLETE RESPONSE LETTER FROM FDA ON OR BEFORE ITS OCTOBER 19, 2019 PDUFA GOAL DATE.CLEARSIDE BIOMEDICAL INC - BELIEVES FDA WILL REVIEW NDA WITHIN SIX MONTHS OF RECEIPT OF RESUBMISSION.CLEARSIDE BIOMEDICAL INC - CONTINUE TO EXPECT THAT WE WILL HAVE SUFFICIENT RESOURCES TO FUND OPERATIONS INTO Q3 OF 2020.CLEARSIDE BIOMEDICAL INC - DISCUSSIONS WITH POTENTIAL XIPERE OUT-LICENSING PARTNERS REMAIN ONGOING.CLEARSIDE BIOMEDICAL INC - FDA'S OPQ REQUESTED CO PROVIDE STABILITY DATA FOR TA SUSPENSION PRODUCED UTILIZING ENHANCED MANUFACTURING PROCESS.CLEARSIDE BIOMEDICAL INC - REQUESTED DATA DOES NOT RELATE TO OR AFFECT SCS MICROINJECTOR PLATFORM.  Full Article

Clearside Biomedical Announces License Agreement With Aura Biosciences
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES LICENSE AGREEMENT WITH AURA BIOSCIENCES FOR SUPRACHOROIDAL SPACE MICROINJECTOR™ DESIGNED TO OPTIMIZE OCULAR ONCOLOGY DRUG DELIVERY.CLEARSIDE BIOMEDICAL INC - CO ELIGIBLE TO RECEIVE PAYMENTS RELATED TO PRE-SPECIFIED DEVELOPMENT, REGULATORY AND SALES MILESTONES.CLEARSIDE BIOMEDICAL INC - CO IS ELIGIBLE TO RECEIVE ROYALTIES ON PRODUCT SALES THAT UTILIZE SCS MICROINJECTOR.CLEARSIDE BIOMEDICAL INC - IF COLLABORATION PROVES SUCCESSFUL, AURA MAY UTILIZE SCS MICROINJECTOR FOR CERTAIN FUTURE DEVELOPMENT PROGRAMS.  Full Article

Clearside Biomedical Appoints George Lasezkay As Interim CEO
Monday, 8 Apr 2019 

April 8 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL APPOINTS DR. GEORGE LASEZKAY AS INTERIM CEO.CLEARSIDE BIOMEDICAL INC - LASEZKAY SUCCEEDS DANIEL H. WHITE.CLEARSIDE BIOMEDICAL INC - BOARD IS INITIATING A SEARCH TO IDENTIFY A PERMANENT CEO.CLEARSIDE BIOMEDICAL INC - WHITE RESIGNED AS PRESIDENT AND CEO AND AS A MEMBER OF BOARD.  Full Article

Clearside Biomedical Posts Q4 Loss Per Share of $0.68
Wednesday, 13 Mar 2019 

March 12 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.68.Q4 EARNINGS PER SHARE ESTIMATE $-0.57 -- REFINITIV IBES DATA.XIPERE NDA ACCEPTED AND ON TRACK FOR OCTOBER 19, 2019 PDUFA DATE.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $40.9 MILLION AS OF DECEMBER 31, 2018.  Full Article

Clearside Biomedical Receives Notification Of FDA Acceptance Of NDA Filing For Xipere
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL RECEIVES NOTIFICATION OF FDA ACCEPTANCE OF NDA FILING FOR XIPERE™ (TRIAMCINOLONE ACETONIDE OPHTHALMIC SUSPENSION) FOR SUPRACHOROIDAL INJECTION WITH PDUFA DATE SET FOR OCTOBER 19, 2019.CLEARSIDE BIOMEDICAL INC - FDA HAS DETERMINED THAT APPLICATION IS SUFFICIENTLY COMPLETE TO PERMIT A SUBSTANTIVE REVIEW..  Full Article

Clearside Biomedical Q3 Loss Per Share $0.75
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.75.Q3 EARNINGS PER SHARE VIEW $-0.63 -- THOMSON REUTERS I/B/E/S.BELIEVES IT WILL HAVE SUFFICIENT RESOURCES TO FUND ITS PLANNED OPERATIONS INTO Q1 OF 2020.  Full Article

Clearside Biomedical announces Sapphire phase 3 study of combination therapy in retinal vein occlusion did not meet its primary endpoint
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES SAPPHIRE PHASE 3 STUDY OF COMBINATION THERAPY IN RETINAL VEIN OCCLUSION DID NOT MEET ITS PRIMARY ENDPOINT.CLEARSIDE BIOMEDICAL INC - FOCUSING RESOURCES ON UVEITIS PROGRAM; NDA FILING EXPECTED Q4 2018.CLEARSIDE BIOMEDICAL - PLAN TO DISCONTINUE CLINICAL DEVELOPMENT OF COMBINATION THERAPY FOR RVO.  Full Article

Clearside Biomedical Q4 Loss Per Share $0.65
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.65.Q4 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S.  Full Article

Clearside Proposes Public Offering Of $75 Mln Of Shares
Wednesday, 7 Mar 2018 

March 6 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CLEARSIDE BIOMEDICAL INC SAYS IT INTENDS TO OFFER AND SELL $75 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.CLEARSIDE BIOMEDICAL INC - ‍INTENDS TO OFFER $75 MILLION SHARES OF ITS COMMON STOCK IN PUBLIC OFFERING​.  Full Article